苦参素联合胸腺肽α1治疗失代偿期肝硬化的抗病毒疗效

摘要

Objective To investigate the clinical effect of antiviral therapy of oxymatrine combined with thymosin alpha 1 on decompensated cirrhosis.Methods 48 cases of patients with hepatitis C cirrhosis treated in our hospital from March 2013 to May 2015 were selected as the study subjects. All the patients were randomly divided into two groups, 24 cases in the observation group and 24 cases in the control group. All patients were treated by basic treatment of protecting liver and reducing enzyme, albumin, based on observed group of patients treated with matrine, thymosin alpha 1 treatment.Results After treatment, the observation group, the level of serum HCV-RNA (3.36±1.30) IU/ml, control group, the level of serum HCV-RNA (4.45±1.42) IU/ml, compared with before treatment, indexes of two groups of patients were significantly decreased, while the observation group was significantly lower (P<0.05). The improvement of liver function in the observation group was significantly better than that in the control group (P<0.05). Conclusion Oxymatrine combined with thymosin α1 in the treatment of lost decompensated cirrhosis strong antiviral effect, can effectively inhibit the virus, the liver cells to the protective effects, alleviating liver injury, high security.%目的：探讨苦参素联合胸腺肽α1对失代偿期肝硬化的抗病毒治疗的临床效果。方法选取2013年3月～2015年5月我院收治的48例失代偿期丙型肝炎肝硬化患者作为研究对象，将所有患者随机分成两组，观察组24例，对照组24例。所有患者均接受保肝降酶、白蛋白的基础治疗，在此基础上，观察组患者接受苦参素、胸腺肽α1治疗。结果治疗后，观察组患者血清HCV-RNA（3.36±1.30）IU/ml，对照组患者血清HCV-RNA（4.45±1.42）IU/ml，与治疗前比较，两组患者指标均明显下降，同时观察组下降更显著（P＜0.05）。观察组肝功能改善情况优于对照组（P＜0.05）。结论苦参素联合胸腺肽α1治疗失代偿期肝硬化的抗病毒效果显著，可有效将病毒抑制，对肝细胞起到保护作用，缓解肝损伤，安全性较高。